Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT

Ibrutinib, a potent and irreversible small-molecule inhibitor of both Bruton’s tyrosine kinase and interleukin-2 inducible kinase (ITK), has been used to treat relapsed/refractory chronic lymphocytic leukemia (CLL) with prolongation of progression-free and overall survival. Here, we present 27 patie...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Ryan, Christine E., Sahaf, Bita, Logan, Aaron C., O’Brien, Susan, Byrd, John C., Hillmen, Peter, Brown, Jennifer R., Dyer, Martin J. S., Mato, Anthony R., Keating, Michael J., Jaglowski, Samantha, Clow, Fong, Rezvani, Andrew R., Styles, Lori, Coutre, Steven E., Miklos, David B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2016
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5179333/
https://ncbi.nlm.nih.gov/pubmed/27802969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-715284
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia